LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

Search

ESPERION THERAPEUTICS INC

Aperta

SettoreSettore sanitario

2.81 1.81

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.7

Massimo

2.81

Metriche Chiave

By Trading Economics

Entrata

28M

-13M

Vendite

17M

82M

EPS

-0.206

Margine di Profitto

-15.446

Dipendenti

304

EBITDA

37M

16M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+157.91% upside

Dividendi

By Dow Jones

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

211M

506M

Apertura precedente

1

Chiusura precedente

2.81

Notizie sul Sentiment di mercato

By Acuity

50%

50%

185 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

ESPERION THERAPEUTICS INC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 set 2025, 17:03 UTC

I principali Market Mover

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 set 2025, 16:49 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

GD Culture Shares Drop After Deal for Pallas Capital

16 set 2025, 16:11 UTC

I principali Market Mover

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 set 2025, 23:40 UTC

Discorsi di Mercato

Nikkei May Decline as Yen Strengthens -- Market Talk

16 set 2025, 23:34 UTC

Discorsi di Mercato

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 set 2025, 23:20 UTC

Discorsi di Mercato

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 set 2025, 21:10 UTC

Acquisizioni, Fusioni, Takeovers

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 set 2025, 20:51 UTC

Discorsi di Mercato

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 set 2025, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

16 set 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

16 set 2025, 20:25 UTC

Utili

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 set 2025, 20:24 UTC

Utili

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 set 2025, 19:19 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 set 2025, 18:52 UTC

Discorsi di Mercato

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 set 2025, 18:44 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

16 set 2025, 18:44 UTC

Discorsi di Mercato

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 set 2025, 18:40 UTC

Acquisizioni, Fusioni, Takeovers

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 set 2025, 18:38 UTC

Discorsi di Mercato

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 set 2025, 18:19 UTC

Discorsi di Mercato

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 set 2025, 18:01 UTC

Discorsi di Mercato

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 set 2025, 17:34 UTC

Discorsi di Mercato

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 set 2025, 16:53 UTC

Utili

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 set 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

16 set 2025, 16:15 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Commodities Roundup: Market Talk

16 set 2025, 16:09 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Energy Roundup: Market Talk

16 set 2025, 16:09 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 set 2025, 15:35 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

16 set 2025, 15:35 UTC

Discorsi di Mercato

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 set 2025, 15:22 UTC

Discorsi di Mercato

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 set 2025, 15:21 UTC

Discorsi di Mercato

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Confronto tra pari

Modifica del prezzo

ESPERION THERAPEUTICS INC Previsione

Obiettivo di Prezzo

By TipRanks

157.91% in crescita

Previsioni per 12 mesi

Media 7.17 USD  157.91%

Alto 16 USD

Basso 1.5 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per ESPERION THERAPEUTICS INC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

2

Acquista

0

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

0.85 / 1.05Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

185 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
help-icon Live chat